Pressmeddelande -

Brighter Presents at Medtech Investment Day Scandinavia in Stockholm

During an all day event, organized by the Nordic medtech industry organizations, leading institutional and private investors are brought together with carefully selected companies of the future.

Medtech Investment Day Scandinavia, taking off at September 8, brings together Scandinavian medtech firms that seek partnerships or expansion capital with venture capitalists, business angels, and private and industrial investors. The event also provides an excellent opportunity to increase business networks in an informal environment with focus on global medtech.

We look forward to this opportunity to present our investment offer before an international public characterized by industry knowledge and with a focus on global medtech.” says Truls Sjöstedt, CEO.

During the period August 15 to September 26, there is a unique opportunity to issue shares in Brighter. During this period, the company will give a large number of presentations, of which various will be open to the public. If you want to get updated on occasions in your proximity, send in your contact details and your place of residence to: presentation@brightercompany.com.

 

About Brighter AB (publ)

Brighter develops and commercializes innovative solutions for diabetes self-care. It is a STING Alumni company. Financing has come from state and institutional investors such as ALMIInnovationsbron, KAS Innovationsfond (a part of the Karl-Adam Bonnier foundation) as well as from private investors.

During the period August 15 to September 26, there is a unique opportunity to participate in the initial public offering and buy shares in Brighter. After the initial public offering, Brighter will be listed at AktieTorget. For more information: www.BrighterCompany.com.

Brighter's all-in-one solution: Brighter One TM Full Video

 

Contact Information

http://www.BrighterCompany.com/

http://www.BrighterCompany.com/video

http://www.facebook.com/brightercompany

http://twitter.com/Brighter_AB


Phone: +46 8 55 00 88 20

Fax: +46 8 55 00 88 30


Truls Sjöstedt, VD på Brighter AB (publ)

Phone: +46 709 73 46 00

E-mail: truls.sjostedt@brightercompany.com

 

Relaterade länkar

Ämnen

  • Företagande

Kategorier

  • self care
  • brighter
  • diabetes
  • ipo
  • aktietorget
  • shares
  • investment
  • presentation
  • medtech

Brighter develops and commercializes innovative solutions for diabetes self-care. It is a STING Alumni company. Financing has come from state and institutional investors such as ALMIInnovationsbron, KAS Innovationsfond (a part of the Karl-Adam Bonnier foundation) as well as from private investors.

During the period August 15 to September 26, there is a unique opportunity to participate in the initial public offering and buy shares in Brighter. After the initial public offering, Brighter will be listed at AktieTorget. For more information: www.BrighterCompany.com.

Brighter's all-in-one solution: Brighter One TM Full Video

Kontakter

  • Brighter One TM
    Licens:
    All rights reserved
  • Investeringsmemorandum
    Investeringsmemorandum
    Licens:
    All rights reserved
    Filformat:
    .pdf
  • Inbjudan till att teckna aktier
    Inbjudan till att teckna aktier
    Licens:
    All rights reserved
    Filformat:
    .pdf
  • Teckningssedel
    Teckningssedel
    Licens:
    All rights reserved
    Filformat:
    .pdf

Relaterat innehåll

  • Brighter Has Launched Its Initial Public Offering Period

    Brighter AB (publ) has launched its Initial Public Offering period at AktieTorget as promised. The company has developed and patented the world’s first all-in-one self-care device for diabetics that does not need to be attached to the body. Now, the public is offered a unique opportunity to take part in Brighter’s future growth through the IPO.

  • Brighter Sheds Light on the Darkness of the Stock Markets

    In the middle of one of the darkest periods on the stock markets, medtech company Brighter AB (publ) invites to its IPO at AktieTorget with the purpose to attract 8.5 MSEK. With the main patent approved a year earlier than planned, Brighter leaves the development period and goes on to commercializing the product portfolio Brighter One TM, an attractive world news with great global potential.

  • Massive Demand – Extended IPO Period

    As the opportunity to issue shares and receive presentations of Brighter One™ has by far surpassed the expectations, the board of Brighter chooses to extend the IPO period until September 26.

  • Global Attention Calls for International Investment Information

    As a result of its patented diabetes device having reached more widespread attention earlier than anticipated, Brighter is releasing a summary of the company’s investment information in English. This information is to accommodate international investors interested in the Swedish medtech company based in Stockholm.